Cell-Free Human Papillomavirus-DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Head and neck cancer
biomarker
cell-free human papillomavirus-DNA
circulating tumor human papillomavirus-DNA
oropharyngeal carcinoma
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
22
06
2021
received:
20
02
2021
accepted:
26
06
2021
pubmed:
9
7
2021
medline:
11
3
2022
entrez:
8
7
2021
Statut:
ppublish
Résumé
The aim of this study was to assess the value of cell-free human papillomavirus-DNA (cfHPV-DNA) as a diagnostic test for the post-treatment surveillance of patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) through a systematic review and meta-analysis. Systematic review and meta-analysis. A literature search was conducted in three databases (MEDLINE, Embase, and Scopus) in January 2021. The population included patients with HPV-positive HNSCC. The intervention was the use of the repeated liquid biopsy with circulating HPV-DNA detection during follow-up. The outcome was to establish the value of cfHPV-DNA as a diagnostic test for the post-treatment surveillance of patients with HPV-positive HNSCC. Ten studies included in the meta-analysis provided a total of 457 patients with HPV-positive HNSCC. The meta-analytic study estimated the diagnostic performance of cfHPV-DNA as follows: pooled sensitivity and specificity of 0.65 (95% confidence interval [CI]: 0.40-0.84) and 0.99 (99% CI: 0.96-0.99), respectively; positive and negative likelihood ratios of 62.5 (99% CI: 22.9-170.2) and 0.05 (99% CI: 0.013-0.24), respectively; and pooled diagnostic odds ratio of 371.66 (99% CI: 60.4-2286.7). Currently, the follow-up protocol for HNSCC patients includes routine clinical evaluation and radiological imaging. Biomarkers to monitor this disease are not established. Considering its high specificity, cfHPV-DNA represents a potential confirmatory test in the case of positive positron emission tomography and computed tomography. In the near future, cfHPV-DNA could be used as a biomarker for monitoring the treatment response during the clinical trials of de-escalation therapy or immunotherapy. Larger sample sizes and the homologation of study protocols and methodology are needed to better establish its utility in the clinical practice. Laryngoscope, 132:560-568, 2022.
Substances chimiques
Cell-Free Nucleic Acids
0
DNA, Viral
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-568Informations de copyright
© 2021 The American Laryngological, Rhinological and Otological Society, Inc.
Références
McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies. Curr Treat Options Oncol 2019;20:43.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6:92.
Windon MJ, D'Souza G, Rettig EM, et al. Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer 2018;124:2993-2999.
Dona MG, Rollo F, Pichi B, et al. Evolving profile of HPV-driven oropharyngeal squamous cell carcinoma in a National Cancer Institute in Italy: a 10-year retrospective study. Microorganisms 2020;8:1498.
Humans IWGotEoCRt. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt B):1-441.
Howard JD, Chung CH. Biology of human papillomavirus-related oropharyngeal cancer. Semin Radiat Oncol 2012;22:187-193.
De Seta D, Campo F, D'Aguanno V, et al. Transoral laser microsurgery for Tis, T1, and T2 glottic carcinoma: 5-year follow-up. Lasers Med Sci 2020;36:507-512.
Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci 2018;19:1706.
Sinha P, Karadaghy OA, Doering MM, Tuuli MG, Jackson RS, Haughey BH. Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: a systematic review and meta-analysis. Oral Oncol 2018;86:121-131.
D'Souza G, Anantharaman D, Gheit T, et al. Effect of HPV on head and neck cancer patient survival, by region and tumor site: a comparison of 1362 cases across three continents. Oral Oncol 2016;62:20-27.
Sedghizadeh PP, Billington WD, Paxton D, et al. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol 2016;54:15-27.
de Virgilio A, Costantino A, Mercante G, et al. Present and future of de-intensification strategies in the treatment of oropharyngeal carcinoma. Curr Oncol Rep 2020;22:91.
Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013;49:79-85.
Campo F, Zocchi J, Ralli M, et al. Laser microsurgery versus radiotherapy versus open partial laryngectomy for T2 laryngeal carcinoma: a systematic review of oncological outcomes. Ear Nose Throat J 2021;100:51S-58S. https://doi.org/10.1177/0145561320928198.
Rulach R, Zhou S, Hendry F, et al. 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers. Oral Oncol 2019;97:76-81.
di Maio P, Iocca O, de Virgilio A, et al. Narrow band imaging in head and neck unknown primary carcinoma: a systematic review and meta-analysis. Laryngoscope 2020;130:1692-1700.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536.
Hilke FJ, Muyas F, Admard J, et al. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. Radiother Oncol 2020;151:182-189.
Tanaka H, Takemoto N, Horie M, et al. Circulating tumor HPV DNA complements PET-CT in guiding management after radiotherapy in HPV-related squamous cell carcinoma of the head and neck. Int J Cancer 2021;148:995-1005.
Rutkowski TW, Mazurek AM, Snietura M, et al. Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. J Transl Med 2020;18:167.
Nguyen B, Meehan K, Pereira MR, et al. A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Sci Rep 2020;10:6083.
Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 2020;38:1050-1058.
Veyer D, Wack M, Mandavit M, et al. HPV circulating tumoral DNA quantification by droplet-based digital PCR: a promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers. Int J Cancer 2020;147:1222-1227.
Lee JY, Garcia-Murillas I, Cutts RJ, et al. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer 2017;117:876-883.
Dahlstrom KR, Li G, Hussey CS, et al. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer 2015;121:3455-3464.
Cao H, Banh A, Kwok S, et al. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2012;82:e351-e358.
Ahn SM, Chan JY, Zhang Z, et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg 2014;140:846-854.
Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-162.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-1135.
Jensen KK, Gronhoj C, Jensen DH, von Buchwald C. Circulating human papillomavirus DNA as a surveillance tool in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Clin Otolaryngol 2018;43:1242-1249.
Wuerdemann N, Jain R, Adams A, et al. Cell-free HPV-DNA as a biomarker for oropharyngeal squamous cell carcinoma-a step towards personalized medicine? Cancers (Basel) 2020;12:2997.
Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018;10:1758835918794630.
Fusconi M, Campo F, Gallo A, et al. Laryngeal cancer, HPV DNA vs E6/E7 mRNA test: a systematic review. J Voice 2017;31:248.e1-248.e5.
Krasniqi E, Barba M, Venuti A, et al. Circulating HPV DNA in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives. J Clin Med 2021;10:1525.
Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017;377:513-522.
Lee VH, Kwong DL, Leung TW, et al. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget 2017;8:5292-5308.
Vainshtein JM, Spector ME, Stenmark MH, et al. Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 2014;50:234-239.
Pellini R, Manciocco V, Turri-Zanoni M, et al. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease. J Craniomaxillofac Surg 2014;42:1834-1839.
Wotman M, Ghaly M, Massaro L, et al. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: an institutional experience. Am J Otolaryngol 2019;40:684-690.
van der Putten L, van den Broek GB, de Bree R, et al. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck 2009;31:593-603.
Clavel S, Charron MP, Belair M, et al. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012;82:567-573.
Hamoir M, Ferlito A, Schmitz S, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol 2012;48:203-210.
Pellini R, Campo F, Sergi D, Cappuzzo F. Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. Oral Oncol 2021;115:105133.
Galvis MM, Borges GA, Oliveira TB, et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2020;150:102966.
Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol 2019;9:682.